Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 53

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 53
---
 and biotechnology companies that are pursuing other forms of treatment for the same indications we are pursuing and that
have greater financial and other resources. Other companies may succeed in developing products earlier than us, obtaining FDA approval
for products more rapidly, or developing products that are more effective than our product candidates. Research and development by others
may render our technology or product candidates obsolete or noncompetitive or result in treatments or cures superior to any therapy we
develop. We face competition from companies that internally develop competing technology or acquire competing technology from universities
and other research institutions. As these companies develop their technologies, they may develop competitive positions that may prevent,
make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we would be able to derive
from the sale of any products.

There can be no assurance
that any of our product candidates will be accepted by the marketplace as readily as these or other competing treatments. Furthermore,
if our competitors’ products are approved before ours, it could be more difficult for us to obtain approval from the FDA. Even if
our products are successfully developed and approved for use by all governing regulatory bodies, there can be no assurance that physicians
and patients will accept our product(s) as a treatment of choice.

Furthermore, the pharmaceutical
research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewith are numerous and significant.
The effects of competition, intellectual property disputes, market acceptance, and FDA regulations preclude us from forecasting revenues
or income with certainty or even confidence.

We
have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently
profitable, and we may never achieve or sustain profitability. 

We were formed in September
2015 and have only a limited operating history and have incurred losses since our formation. We continue to incur significant development
and other expenses related to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses
in each period since our inception, resulting in substantial doubt in our ability to continue as a going concern. We reported a net loss
of $42.1 million and $30.0 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, we
had cash and cash equivalents of $20.9 million and $35.8 million, respectively.

We expect to continue to